Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
Phase 1
Withdrawn
- Conditions
- Schizophrenia
- Interventions
- Drug: NSA-789 at 2 different doses
- Registration Number
- NCT00781794
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in nonsmoking patients with schizophrenia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 2 NSA-789 at 2 different doses Dose 2 3 NSA-789 at 2 different doses - 1 NSA-789 at 2 different doses Dose 1
- Primary Outcome Measures
Name Time Method electroencephalogram 8 weeks
- Secondary Outcome Measures
Name Time Method blood sample 8 weeks